CAR-T Following ASCT for Relapsed/Refractory B-Cell Non-Hodgkin's Lymphoma (R/R B-NHL) With High-Risk Prognostic Factors

This study is testing whether CAR-T cell therapy (a type of personalized immune cell treatment) given after a stem cell transplant can reduce the risk of relapse in people with aggressive B-cell lymphoma who have specific high-risk features. **You may be eligible if...** - You have been diagnosed with a type of B-cell non-Hodgkin's lymphoma (such as diffuse large B-cell lymphoma or related subtypes) - You have achieved remission or have limited remaining disease after chemotherapy - You are planned for or have undergone an autologous stem cell transplant - You are between 18 and 70 years old with adequate organ function **You may NOT be eligible if...** - You have active infection or uncontrolled illness - Your cancer has progressed after the stem cell transplant - You have received prior CAR-T cell therapy - You are pregnant or breastfeeding Talk to your doctor to see if this trial is right for you.